Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Claritas Pharmaceuticals Inc V.CLAS.H

Alternate Symbol(s):  CLAZF

Healthcare
Claritas Pharmaceuticals, Inc., formerly Kalytera Therapeutics Inc, is a biotechnology company that is focused on developing R-107 for the treatment of vaccine-resistant coronavirus disease (COVID) strains. The Company’s products in development include R-107 for coronavirus disease and Viral Infections, R-107 and Vaccines, and CLA-1816 for treatment of pain. R-107 is designed to defeat COVID viruses on contact. R-107 targets the Achilles heel of COVID, the spike protein on the surface of the virus. R-107 releases nitric oxide, which attaches to a specific amino acid on the spike protein, thereby disabling the spike protein. The CLA-1816 provides effective pain reduction, without the risks of addiction or respiratory suppression that exist with opioid analgesics. CLA-1816 strongly binds with and activates the alpha3 glycine pain receptor in the spine. The Company has leased a laboratory, office, and archival space in Beverly, Massachusetts.


TSXV:CLAS.H - Post by User

Claritas Pharmaceuticals Inc > Explosive Friday!!!!
<< Previous
 Bullboard Posts
Next >>
User Avatar Image
(197)
•••
Post by Maui527on Feb 24, 2021 10:20pm
472 Views
Post# 32655027

Explosive Friday!!!!

Explosive Friday!!!!Here is my prediction folks!

Open minimum $0.055(most recent resistance)....Close Friday at $0.20...(Next level of Resistance)...

Then Monday...gap open with a run to $0.40 (next resistance)

Then Tuesday...gap open with a run to $0.60 (next resistance)

View the chart and tell me I am wrong!

Remember on Feb 5th when KALTF resumed trading in the US because they could and the price shot up to $0.10 US...well those were shorts covering on the KALTF side!

Last I remember, not showing anymore because it has been so long, but there was in excess of 95,000,000 million shares short going into the halt. Well, guess what they will have to cover, and they will want to right away. If you do not think this will drive the price up through the roof, you are kidding yourself.

I have 1 million shares and I will not be selling a single share, in fact I will buy at market first thing Friday morning, minimum 500k shares. ( I have to put by crypto gains somewhere)..Ha Ha Ha!!!

We are in for one hell of a ride come Friday morning! I strongly encourage all current share holders, to not sell....let this ride out, as the less shares available will only drive the share price to the moon!!!

It has been on heck of a long ride, but the next 36 hours will be the hardest!

Good luck longs and stay safe! 
<< Previous
 Bullboard Posts
Next >>
Dealroom for high-potential pre-IPO opportunities